EMEA-002027-PIP02-17-M01

Key facts

Active substance
  • Influenza virus surface antigens (haemagglutinin) of strain A (H1N1)
  • influenza virus surface antigens (haemagglutinin) of strain A (H3N2)
  • influenza virus surface antigens (haemagglutinin) of strain B  (Victoria lineage)
  • influenza virus surface antigens (haemagglutinin) of strain B (Yamagata lineage)
Therapeutic area
Infectious diseases
Decision number
P/0340/2019
PIP number
EMEA-002027-PIP02-17-M01
Pharmaceutical form(s)
Suspension for injection
Condition(s) / indication(s)
Prevention of influenza infection
Route(s) of administration
Intramuscular use
Contact for public enquiries
Adimmune Corporation (Taiwan)

Tel.: +886 425381220 ext.1809
E-mail: wendy_tsen@adimmune.com.tw

Decision type
W: decision granting a waiver in all age groups for all conditions/indications

Decision

How useful was this page?

Add your rating